Compare ZGM & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZGM | CTXR |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | Macau | United States |
| Employees | 9 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 18.9M |
| IPO Year | N/A | 2010 |
| Metric | ZGM | CTXR |
|---|---|---|
| Price | $1.65 | $0.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 10.3K | ★ 434.4K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | $20.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.09 | $0.63 |
| 52 Week High | $4.44 | $2.38 |
| Indicator | ZGM | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 51.33 | 50.39 |
| Support Level | $1.38 | $0.66 |
| Resistance Level | $1.87 | $0.98 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 71.79 | 52.80 |
Zenta Group Co Ltd is a professional services provider in Macau, offering industrial park consulting services, business investment consulting services through LIC, and the sale of fintech products and services through LFT. Its industrial park consulting services focus on the pre-development stage, assisting with applications and negotiations for industrial park projects with PRC government authorities, with plans to expand into post-development services through LMS. The business investment consulting services mainly involve assisting clients in acquiring equity stakes in technology firms, private equity management firms, and industrial park project firms, supported by third-party professionals. The Group operates in Macau and the PRC, generating the majority of its revenue from the PRC.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.